A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma
Status:
Completed
Trial end date:
2020-03-26
Target enrollment:
Participant gender:
Summary
This study will determine the maximum tolerated dose (MTD) and/or the recommended phase II
dose (RP2D) of single agent ONC201 in patients with advanced solid tumors or multiple
myeloma.